AIDS 2022, the 24th International AIDS Conference, will call on the world to come together to re-engage and follow the science. It will define future research agendas, shift latest evidence to action, and chart a new consensus on overcoming the HIV epidemic as a threat to public health and individual well-being. HVTN researchers and staff are looking forward for the opportunity to learn and connect with colleagues from around the world, as well as presenting recent work.
In addition to the presentations mentioned below, we invite you to come and visit us at our booth in the Global Village. Our location, GVE023, is highlighted in this map (pdf download) for reference.
Presentations
Abstracts
Oral Abstracts:
Immune correlates analysis of the Imbokodo HIV-1 vaccine efficacy trial
Kenny A, Luedtke A, Hyrien O, Fong Y, Burnham R, Heptinstall J, Sawant S, Stanfield-Oakley S, Omar FL, Khuzwayo S, Dintwe O, Borducchi E, Pattacini L, Willems W, Lavreys L, van Duijn J, Stieh DJ, Tomaka F, Pau MG, Gray GE, Buchbinder S, Mngadi K, McElrath MJ, Corey L, Barouch DH, De Rosa SC, Ferrari G, Andersen-Nissen E, Tomaras G, Gilbert PB
High prevalence of asymptomatic Omicron carriage and correlation with CD4+ T-cell count among adults with HIV enrolling in COVPN 3008 Ubuntu clinical trial in sub-Saharan Africa
Tapley A, Andriesen K, Fisher L, Huang Y, Ketter N, Villaran M, Gilbert P, Hural J, Yacovone M, Bekker LG, Corey L, Gray GE, Makhema J, Nuwagaba-Biribonwoha H, Samadari T, Elyanu PJ, Chilengi R, Chirenje Z, Dadabhai S, Mgodi N, Kotze P, Garrett N
Posters:
Analysis of the HVTN 702 Phase 2b-3 HIV-1 vaccine trial in South Africa assessing RV144 antibody and T-cell correlates of HIV-1 acquisition risk
Moodie Z, Sawant S, Dintwe O, Grove D, Huang Y, Janes H, Heptinstall J, Laher Omar F, Cohen K, De Rosa SC, Zhang L, Yates NL, Sarzotti-Kelsoe M, Seaton KE, Laher F, Bekker LG, Malahleha M, Innes C, Kassim S, Naicker N, Govender V, Sebe M, Singh N, Kotze P, Lazarus E, Nchabeleng M, Ward AM, Brumskin W, Dubula T, Randhawa AK, Grunenberg N, Jin Kee J, Carpp LN, Hural J, Allen M, D'Souza P, Tartaglia J, DiazGranados CA, Koutsoukos M, Gilbert PB, Kublin JG, Corey L, Andersen-Nissen E, Gray GE, Tomaras GD, McElrath MJ, HVTN 702 Protocol Team
Administration of the broadly neutralizing, CD4-binding site targeting antibody VRC07-523LS in dual- and triple-antibody combinations with 10-1074, PGT121, and/or PGDM1400: impact on pharmacokinetics compared to VRC07-523LS administration alone
Walsh S, Gay C, Sobieszczyk M, Mannheimer S, Hyrien O, Yu C, Seaton K, Skalland T, Dumond J, Andrew P, Karg C, Paez C, Gamble T, He Z, Hanscom B, Dye B, Piwowar-Manning E, Hural J, Polakowski L, Yacovone M, Chege W, Montefiori D, Gama L, Mascola J, Tomaras G, Huang Y, Karuna S, HVTN127/HPTN087 and HVTN130/HPTN089 Study Teams
Utilizing standardized metrics to track recruitment strategies in a global preventive HIV vaccine study during the COVID-19 pandemic
Gonzalez R, Kamel L, Segura Marquez PM, Corbelli GM, Broder GB, Wallace S
First-in-human evaluation of safety and pharmacokinetics of intravenous or subcutaneous infusions of PGT121.141.LS, an anti-V3 HIV-1 broadly neutralizing monoclonal antibody in healthy volunteers without HIV
Edupuganti S, Hurt CB, Stephenson KE, Huang Y, Paez CA, Gamble T, Yu C, Yen C, Regenold S, Chege W, Heptinstall J, Seaton KE, Montefiori DC, Tomaras G